| HOME >> BIOLOGY >> TECHNOLOGY |
months ended June 30, 2007
and 2006, respectively) 2,523 2,532 37,111
BUSINESS DEVELOPMENT COSTS
(includes non-cash stock option
compensation of $11 and $1, for
the six months ended June 30,
2007 and 2006, respectively,
and also includes stock
appreciation rights compensation
of $565 for the six months ended
June 30, 2007) 828 168 5,982
----------- ----------- ---------
OPERATING LOSS 15,213 7,508 137,954
FINANCIAL AND OTHER INCOME, net 351 323 8,635
----------- ----------- ---------
LOSS BEFORE INCOME TAXES 14,862 7,185 129,319
INCOME TAXES (213) 106 253
----------- ----------- ---------
LOSS FOR THE PERIOD 14,649 7,291 129,572
----------- ----------- ---------
BASIC AND DILUTED LOSS PER $ 0.07 $ 0.04
ORDINARY SHARE
WEIGHTED AVERAGE NUMBER OF
SHARES USED IN COMPUTING BASIC
AND DILUTED LOSS PER ORDINARY
SHARE 220,145,233 183,085,938
----------- -----------
(*) Incorporation date see note 1.
Interim Consolidated Statements of Changes in Shareholders'
Equity for the Six Months Ended June 30, 2007 (unaudited)
(in thousands of US dollars, except share amounts)
Ordinary shares
-------------------- Additional
Number of paid in
'/>"/>
SOURCE XTL Biopharmaceuticals Ltd![]() Copyright©2007 PR Newswire. |